New drug combo targets tough cancers in early trial

NCT ID NCT06049212

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will take part to find the best dose and see how the body handles the drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER PROGRAMMED CELL DEATH 1 LIGAND 1(PDL1, PD-L1) PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2) PROGRAMMED CELL DEATH-1 (PD1, PD-1) SOLID TUMORS

Contacts and locations

Locations

Aichi Cancer Center ( Site 0006)

Nagoya, Aichi-ken, 464-8681, Japan
Kanagawa Cancer Center ( Site 0004)

Yokohama, Kanagawa, 241-8515, Japan
Kansai Medical University Hospital ( Site 0007)

Hirakata, Osaka, 573-1191, Japan
National Cancer Center Hospital ( Site 0001)

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East ( Site 0002)

Kashiwa, Chiba, 277-8577, Japan
National Hospital Organization Shikoku Cancer Center ( Site 0008)

Matsuyama, Ehime, 791-0280, Japan
Shizuoka Cancer Center ( Site 0005)

Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.